MBX Biosciences, Inc
2:00 PM - 2:15 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX 2109, its lead product candidate in development for the treatment of hypoparathyroidism (HP), is currently in a Phase 1 clinical trial.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Indiana
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
MBX 2109
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
